États-Unis · Plateformes & données · Morningstar

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Publié par Morningstar · États-Unis il y a 1 j

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

À lire aussi

We have a $300,000 mortgage with a 2.75% interest rate. I want to pay it off. My husband says I’m crazy. Who’s right?

Volatus Aerospace Inc. (FLT.TO) - What Are Brokerages Saying About This Stock?

General Motors' Q3 Sales Slipped. Its Profits Soared. Here Are 3 Takeaways Investors Must Note.

Lam Research earnings beat by $0.02, revenue topped estimates

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Partager

À lire aussi

We have a $300,000 mortgage with a 2.75% interest rate. I want to pay it off. My husband says I’m crazy. Who’s right?

Volatus Aerospace Inc. (FLT.TO) - What Are Brokerages Saying About This Stock?

General Motors' Q3 Sales Slipped. Its Profits Soared. Here Are 3 Takeaways Investors Must Note.

Lam Research earnings beat by $0.02, revenue topped estimates

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030